Colorectal Cancer Clinical Trials

38 trials recruiting in Canada.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

23 trials

Comparing 10 approaches for metastatic colorectal cancer

Explore this study →

There are 10 groups in this study. Group A receives Inavolisib and Cetuximab, together with one or more of: FoundationOne®Liquid CDx. Group B receives Inavolisib and Bevacizumab, together with one or more of: FoundationOne®Liquid CDx. Group C receives Atezolizumab, Tiragolumab and Bevacizumab, together with one or more of: FoundationOne®Liquid CDx. …and 7 more groups.

Sites in Montreal and Toronto

Phase 1
10 groups
Sites in Toronto and Montreal
Recruiting

Official title: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Metastatic Colorectal Cancer · Hoffmann-La Roche

Comparing 3 approaches for metastatic colorectal cancer

Explore this study →

There are 3 groups in this study. Group A receives Precemtabart tocentecan. Group B receives Bevacizumab, together with one or more of: Precemtabart tocentecan. Group C, the comparison group, receives Trifluridine/Tipiracil (FTD-TPI) and Bevacizumab.

Sites in Ottawa, Toronto and 1 more city

Phase 3
3 groups
Sites in Vancouver, Ottawa and 1 more city
Recruiting

Official title: A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic Colorectal Cancer · EMD Serono Research & Development Institute, Inc.

Comparing Drug: Ivonescimab with Drug: Bevacizumab for metastatic colorectal cancer (CRC)

Explore this study →

There are 2 groups in this study. Group A receives Drug: Ivonescimab Injection. Group B, the comparison group, receives Drug: Bevacizumab Injection.

Sites in Brampton, Montreal and 3 more cities

Phase 3
2 groups
Sites in Vancouver, Brampton and 3 more cities
Recruiting

Official title: Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC) · Summit Therapeutics

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for colorectal cancer.

Comparing 4 approaches for stage III colon cancer

Explore this study →

There are 4 groups in this study. Group A, the comparison group, receives one or more of: Signatera test, mFOLFOX6 3-6 month and CAPOX 3 month. Group B receives Signatera test. Group C, the comparison group, receives one or more of: Signatera test, mFOLFOX6 6 month and CAPOX 6 month. …and 1 more groups.

Sites in Toronto, Montreal and 24 more cities

Phase 2
4 groups
Sites in Calgary, Prince George and 23 more cities
Recruiting

Official title: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Stage III Colon Cancer · NRG Oncology

Comparing Amivantamab with Cetuximab for colorectal neoplasms

Explore this study →

There are 2 groups in this study. Group A receives Amivantamab, together with one or more of: 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin and Irinotecan Hydrochloride. Group B, the comparison group, receives Cetuximab, together with one or more of: 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin and Irinotecan Hydrochloride.

Sites in Calgary, Montreal and 2 more cities

Phase 3
2 groups
Sites in Calgary, Ottawa and 2 more cities
Recruiting

Official title: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms · Janssen Research & Development, LLC

Comparing Stereotactic Ablative Radiotherapy with Chemotherapy for metastatic colorectal adenocarcinoma

Explore this study →

There are 2 groups in this study. Group A receives Chemotherapy, together with one or more of: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Computed Tomography, Magnetic Resonance Imaging and Positron Emission Tomography. Group B, the comparison group, receives Chemotherapy, together with one or more of: Computed Tomography, Magnetic Resonance Imaging and Positron Emission Tomography.

One site, in Calgary

Phase 2
2 groups
One site, in Calgary
Recruiting

Official title: Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Metastatic Colorectal Adenocarcinoma · Alliance for Clinical Trials in Oncology

Testing INCA33890 with Bevacizumab against a placebo for CRC (colorectal cancer)

Explore this study →

There are 2 groups in this study. Group A receives INCA33890, together with one or more of: Bevacizumab and FOLFOX. Group B, the placebo group, receives Placebo, together with one or more of: Bevacizumab and FOLFOX.

Sites in Toronto, Edmonton and 5 more cities

Phase 3
2 groups
Sites in Edmonton, Hamilton and 5 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

CRC (Colorectal Cancer) · Incyte Corporation

Comparing 3 approaches for colorectal cancer

Explore this study →

There are 3 groups in this study. Group A receives Sacituzumab tirumotecan, together with one or more of: Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication and Supportive care measures. Group B receives Sacituzumab tirumotecan, together with one or more of: Rescue medication and Supportive care measures. Group C receives Sacituzumab tirumotecan, Cisplatin and Pembrolizumab, together with one or more of: Rescue medication and Supportive care measures.

Sites in Montreal and Ottawa

Phase 1
3 groups
Sites in Ottawa and Montreal
Recruiting

Official title: A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Colorectal Cancer · Merck Sharp & Dohme LLC

Testing Nivolumab with HDRBET for locally advanced rectal cancer

Explore this study →

Everyone in this study receives Nivolumab, together with one or more of: HDRBET and Total Mesorectal Excision (TME).

One site, in Montreal

Phase 2
1 group
One site, in Montreal
Recruiting

Official title: Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

Locally Advanced Rectal Cancer · Dr. Te Vuong

Comparing 9 approaches for colorectal cancer

Explore this study →

There are 9 groups in this study. Groups A, B, C, D, E and F receive BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI). Groups G, H and I, the comparison group, receive BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII).

Sites in Montreal, Edmonton and 3 more cities

Phase 1
9 groups
Sites in Edmonton, Hamilton and 3 more cities
Recruiting

Official title: BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

Colorectal Cancer · Bold Therapeutics, Inc.

Comparing 8 approaches for metastatic colorectal cancer

Explore this study →

There are 8 groups in this study. Groups A, B and C receive Telisotuzumab Adizutecan, together with one or more of: Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab. Group D receives one or more of: Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab. Groups E, F and G receive Telisotuzumab Adizutecan, together with one or more of: Fluorouracil, Leucovorin and Panitumumab. …and 1 more groups.

Sites in Calgary, Edmonton and 3 more cities

Phase 2
8 groups
Sites in Calgary, Edmonton and 3 more cities
Recruiting

Official title: A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer · AbbVie

Comparing 5 approaches for untreated, unresectable, or metastatic colorectal cancer

Explore this study →

There are 5 groups in this study. Groups A and B receive one or more of: Pumitamig, FOLFOX and FOLFIRI. Group C receives one or more of: FOLFOX, FOLFIRI and Bevacizumab. Group D receives one or more of: Pumitamig, FOLFOX, FOLFIRI and CAPOX. …and 1 more groups.

Sites in Montreal, Toronto and 4 more cities

Phase 2
5 groups
Sites in Calgary, Halifax and 4 more cities
Recruiting

Official title: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer · Bristol-Myers Squibb

Testing GSK5460025 for colorectal neoplasms

Explore this study →

There are 2 groups in this study. Groups A and B receive GSK5460025.

Sites in Hamilton, Montreal and 1 more city

Phase 1
2 groups
Sites in Hamilton, Toronto and 1 more city
Recruiting

Official title: A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Neoplasms, Colorectal · GlaxoSmithKline

Testing Floxuridine for colorectal adenocarcinoma metastatic in the liver

Explore this study →

Everyone in this study is in one group and receives Floxuridine (FUDR).

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis

Colorectal Adenocarcinoma Metastatic in the Liver · Sunnybrook Health Sciences Centre

Testing Radiation Therapy with FOLFOX regimen for colorectal carcinoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: Radiation Therapy, FOLFOX regimen and Capecitabine.

One site, in Montreal

Phase 2
1 group
One site, in Montreal
Recruiting

Official title: Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)

Colorectal Carcinoma · Neil Kopek

Comparing 3 approaches for colorectal cancer

Explore this study →

There are 3 groups in this study. Groups A and B receive ONO-4578, Opdivo® and Bevacizumab, together with one or more of: Oxaliplatin, 5-Fluorouracil and Leucovorin. Group C, the comparison group, receives Bevacizumab, together with one or more of: Oxaliplatin, 5-Fluorouracil and Leucovorin.

Sites in Montreal, Ottawa and 1 more city

Phase 2
3 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Colorectal Cancer · Ono Pharmaceutical Co., Ltd.

Comparing tucatinib with bevacizumab for colorectal neoplasms

Explore this study →

There are 2 groups in this study. Group A receives tucatinib, together with one or more of: trastuzumab, oxaliplatin, leucovorin, levoleucovorin and fluorouracil. Group B, the comparison group, receives one or more of: bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin and fluorouracil.

Sites in Toronto, Montreal and 2 more cities

Phase 3
2 groups
Sites in Ottawa, Toronto and 2 more cities
Recruiting

Official title: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Colorectal Neoplasms · Seagen, a wholly owned subsidiary of Pfizer

Testing FOLFOXIRI and Bevacizumab for metastatic colorectal cancer

Explore this study →

Everyone in this study is in one group and receives FOLFOXIRI and Bevacizumab.

One site, in Regina

Phase 2
1 group
One site, in Regina
Recruiting

Official title: Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer · University of Saskatchewan

Comparing Volrustomig with FOLFIRI (Fluorouracil (5-FU), for metastatic colorectal cancer

Explore this study →

There are 2 groups in this study. Group A receives Volrustomig and Bevacizumab, together with one or more of: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan). Group B, the comparison group, receives Bevacizumab, together with one or more of: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan).

Sites in Barrie, Montreal and 2 more cities

Phase 2
2 groups
Sites in Victoria, Barrie and 2 more cities
Recruiting

Official title: A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Metastatic Colorectal Cancer · AstraZeneca

Comparing Sotorasib with Bevacizumab-awwb for metastatic colorectal cancer

Explore this study →

There are 2 groups in this study. Group A receives Sotorasib and Panitumumab, together with one or more of: FOLFIRI Regimen. Group B, the comparison group, receives Bevacizumab-awwb, together with one or more of: FOLFIRI Regimen.

Sites in Toronto, Brampton and 3 more cities

Phase 3
2 groups
Sites in Calgary, Brampton and 3 more cities
Recruiting

Official title: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Metastatic Colorectal Cancer · Amgen

Comparing Leucovorin with Radiation for rectal cancer

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Leucovorin, Oxaliplatin, Fluoruracil and Capecitabine. Group B, the comparison group, receives one or more of: Fluoruracil, Capecitabine and Radiation.

Sites in London, Montreal and 6 more cities

Phase 3
2 groups
Sites in Vancouver, Winnipeg and 6 more cities
Recruiting

Official title: Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Rectal Cancer · Canadian Cancer Trials Group

Comparing 6 approaches for colorectal neoplasms

Explore this study →

There are 6 groups in this study. Group A receives PF-08046050. Group B receives PF-08046050 and bevacizumab. Group C receives PF-08046050 and bevacizumab, together with one or more of: 5-Fluorouracil (5-FU) and Leucovorin (LV). …and 3 more groups.

Sites in Toronto, Montreal and 1 more city

Phase 1
6 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Colorectal Neoplasms · Seagen, a wholly owned subsidiary of Pfizer

Comparing Fleet Enema with Pico-Salax for colorectal neoplasms

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Fleet Enema. Group B, the comparison group, receives Pico-Salax.

One site, in Halifax

Phase 4
2 groups
One site, in Halifax
Recruiting

Official title: TES RCT Fleet Enema vs Oral Mechanical Bowel Prep

Colorectal Neoplasms · Nova Scotia Health Authority

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Colorectal Cancer trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.